Merit Medical price target raised to $109 from $107 at Baird

Baird raised the firm’s price target on Merit Medical (MMSI) to $109 from $107 and keeps an Outperform rating on the shares. The firm said they delivered another beat/raise, with nearly 6% organic revenue growth and 180bps of OM expansion. WRAPSODY launch continues to approach which will be a key growth driver and potential accelerator over the next several years.